Haematologic Technologies Appoints Steve Pemberton as Vice President of Commercial Development

August 31, 2020| Category: Uncategorized

August 31th , 2020 Essex Junction, VT – Haematologic Technologies (HTI), a leading protein chemistry company providing products and analytical services supporting the research, development, and commercialization of large molecule biotherapeutics, today announced the expansion of the Senior Leadership Team with the addition of Steve Pemberton.  Steve is a commercial sales and marketing executive with over 20 years of strategic marketing, business development, sales leadership, and direct sales experience.  Steve will assume the role of Vice President of Commercial Development reporting directly to the CEO, Jean Pineault.

“Haematologic Technologies is well recognized and highly regarded as experts in the area of protein chemistry particularly as applied to the analysis of biopharmaceuticals.  The combination of deep scientific expertise, commitment to quality, and company culture offered me a compelling opportunity to help grow the franchise. I am excited at the opportunity to join the leadership team and work with the team at HTI,” said Steve Pemberton.

“Steve’s energy and passion for linking high quality scientific services to customers was evident from our first conversation, and his demonstrated history at driving revenue and commitment to customer success made him the obvious choice for this position,” said Jean Pineault, President and Chief Executive Officer.

Previous to HTI, Steve was Vice President of Business Development for Bionique Testing Laboratories, a cGMP provider of mycoplasma testing services to the biopharmaceutical industry.  While at Bionique, Steve was responsible for double digit, year over year revenue growth of the organization.  Previous positions have included executive level positions at Rheonix, Inc., a manufacturer of molecular diagnostic devices, where he was Vice President of Marketing and Sales, responsible for business development, marketing, and sales.   Steve has held prior leadership, marketing and sales positions at Abbott Laboratories and Roche Diagnostics.

About Haematologic Technologies:

HTI boasts deep expertise in protein chemistry servicing four distinct market segments. CMC, supporting cell line optimization, host cell proteins, drug substance/product characterization, stability & release, enzyme and coagulation factors replacement therapies among others from early development to commercialization. Pharmacokinetics, potency, and immunogenicity assays supporting drug development from discovery, preclinical, clinical to post marketing. Plasma derived protein therapeutics including hyperimmune plasma products release testing. Specialized clinical diagnostics reagents productions and services.

The company’s biopharma services are performed in fully compliant, FDA-inspected GMP facilities. Building on its 30+ years of expertise in plasma proteins, hemostasis, and blood coagulation, HTI is a leading global supplier of coagulation research reagents (plasma proteins and antibodies), custom formulated IVD/POC device reagents, and customized blood collection tubes for clinical trials. Visit us at www.haemtech.com.